ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant…
U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at…
FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions…
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed…
Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in…
Crossject to amend the Heights Capital Management, Inc. (“Heights”) bonds convertible in new shares or repayable Dijon, FRANCE, December 11,…
BEIJING, Dec. 11, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated…
The Youth Mental Health Tracker, developed by Surgo Health with funding from Pivotal and SHOWTIME/MTV Entertainment Studios, reveals new data…
LAKE CHARLES, La., Dec. 10, 2024 /PRNewswire/ -- Wavegate Corporation, a pioneering developer of neuromodulation technology for chronic pain management,…